Integrilin solution for inf. 0.75mg/ml fl. 100 ml No. 1

Solution for infusions Integrilin is appointed at the following indications:

• Early prevention of a myocardial infarction at patients with unstable stenocardia or a myocardial infarction without tooth of Q which had the last painful attack within 24 hours with changes on the ECG and/or increase in activity of cardiospecific enzymes.
• Treatment of patients with high risk of developing a myocardial infarction within 3-4 days after emergence of symptoms of acute stenocardia, including those which plans performing the percutaneous transluminal coronary angioplasty (PTCA).
Drug is intended to
• for use in a combination with acetylsalicylic acid and unfractionated heparin.

Structure

Active ingredient: eptifibatid;

1 ml of solution; 1 bottle (100 ml) contains 75 mg of an eptifibatid;

Excipients: citric acid monohydrate, sodium hydroxide water for injections.

Contraindication

• Hypersensitivity to medicament components.
• Gastrointestinal bleedings, serious genital and urological bleedings.
• Acute disorder of cerebral circulation during the previous 30 days of treatment or a hemorrhagic stroke in the anamnesis.
• Intracranial diseases in the anamnesis (new growths, arteriovenous malformations, aneurysms).
• Big surgery or a severe injury during 6 weeks the day before.
• Hemorrhagic diathesis in the anamnesis.
• Thrombocytopenia (<100,000 C/mm ³ ).
Prothrombin time is 1.2 times more than
• control or an indicator of INR> 2.0.
• Profound arterial hypertension (systolic pressure> 200 mm Hg. or diastolic pressure> 110 mm Hg.) Against the background of the ABP.
• Clinically apparent abnormal liver function.
• Heavy renal failure (clearance of creatinine <30 ml/min.) or need of carrying out to the patient of renal dialysis.
by
• Simultaneous or planned parenteral use of other blocker of glycoprotein IIb/IIIa of receptors for parenteral administration.

Route of administration

1. Integrilin's Solution before introduction needs to be examined on existence of turbidity and foreign particles; solution can be entered only on condition of their absence. At input, solution of protection against light does not need.
2. For bolyusny introduction needs to be gathered from a bottle on 10 ml of medicament by means of the syringe and to enter intravenously struyno within 1-2 minutes.
needs to begin with
3. Right after bolyusny introduction continuous infusion of Integrilin. When using the infusional pump Integrilin it is necessary to enter in an undiluted view directly from a bottle for infusions (a bottle on 100 ml). The system for Integrilin's input from a bottle of 100 ml has to have an opening for air; the needle for connection of a system to a bottle should be entered strictly through the center of a stopper of a bottle.

Residue of medicament in a bottle is not subject to further use.

Feature of use

Pregnant

should not be applied during pregnancy, except for emergency. Children

it is not recommended by

to p.

Drivers

Integrilin should be applied only in the conditions of a hospital.

Overdose

Information on overdose of an eptifibatid it is very limited. Data on the serious violations connected with accidental overdose at jet or drop introduction and also when exceeding the saved-up dose no.

It was reported about 9 patients, at PURSUIT of a research received a bolyusny and/or drop dose more than twice exceeded recommended. At the same time excessive bleedings at one of patients though it was observed moderated bleeding at one patient to whom aortocoronary shunting was carried out were not observed. In particular at one of patients intracranial bleedings were not observed.

. Through the short term of semi-removal and high clearance the effect of medicament can be quickly stopped ​​ by the introduction termination. Though eptifibatid it can be removed by dialysis, need for it it is improbable.

Side effects

it is frequent (> 1/100, <1/10) it was reported about the undesirable phenomena (> 2% in all groups of examinees), the fibrillations of auricles, arterial hypotension, heart failure, cardiac arrest, shock, tachycardia, fibrillation of ventricles of heart, AV connected with a basic disease, for example, blockade and also phlebitis.

Special researches on studying pharmacokinetic interaction of Integrilin with other medicaments were not conducted by

.

Storage conditions

to Store

at a temperature of 2 °C - 8 °C in the place protected from light.

to Store

out of children's reach.

Expiration date - 3 years.